aMoon

aMoon
Name	aMoon
Type	Private
Industry	Venture capital
Founded	2016
Headquarters	Tel Aviv, Israel
Key people	Ido Schoenberg, Dror Katzav
Products	Healthcare investments, life sciences funds

aMoon

aMoon is a venture capital firm focused on healthcare, biotechnology, and life sciences. Founded in 2016 and headquartered in Tel Aviv, the firm targets growth-stage and early-stage companies across Israel, Europe, and North America, deploying capital into therapeutics, digital health, diagnostics, and medical devices. aMoon operates multiple funds and collaborates with leading research institutions, pharmaceutical companies, and public markets to scale portfolio companies toward exit events such as acquisitions and initial public offerings.

Overview

aMoon operates at the intersection of venture capital and healthcare innovation, investing in companies advancing therapeutics, precision medicine, digital health, and diagnostics. The firm sources deals from ecosystems that include Israeli incubators, academic research at institutions like Weizmann Institute of Science, collaborations with pharmaceutical companies such as Pfizer and Roche, and networks linked to hospitals like Sheba Medical Center. aMoon’s model emphasizes syndication with global investors, participation in board governance, and leveraging public markets exemplified by partnerships with investment banks including Goldman Sachs and Morgan Stanley to support later-stage exits. The firm’s team includes founders and executives with experience at healthcare companies and investment firms such as Teva Pharmaceutical Industries and OrbiMed Advisors.

History and Development

aMoon was founded in 2016 by executives with backgrounds in healthcare entrepreneurship and investment banking, launching amid a surge of interest in Israeli life sciences. Early activity included fundraising rounds tapping sovereign and private wealth sources similar to investors in companies like Mobileye and Wix.com. During its development, aMoon expanded from seed and Series A investments to growth-stage funds, mirroring trajectories seen at firms like Sequoia Capital and Accel. The firm has publicly navigated regulatory environments involving authorities such as the U.S. Food and Drug Administration and the European Medicines Agency when portfolio companies progressed toward clinical trials or market authorization. aMoon’s timeline includes co-investments with strategic partners such as Johnson & Johnson Innovation and participation in consortiums alongside institutions like MIT and Harvard Medical School.

Investment Strategy and Portfolio

aMoon focuses on therapeutic platforms, oncology, neuroscience, rare diseases, and digital health solutions that integrate software with regulated medical products. The portfolio strategy favors companies spun out from university labs—examples of comparable spinouts include ventures from Technion – Israel Institute of Technology and Stanford University—as well as startups led by entrepreneurs who previously founded firms like Claroty or Nanit. The firm allocates capital across seed, Series A, and later-stage rounds, often co-investing with life sciences specialists such as NEA and 3 BioCapital and strategic corporate venture arms like Novartis Venture Fund. Portfolio companies have pursued exit pathways including mergers and acquisitions by multinational firms such as Sanofi and public listings on exchanges like the New York Stock Exchange and NASDAQ.

Financial Performance and Fundraising

aMoon has raised multiple funds targeting institutional and private investors, with fundraising rounds drawing allocations from family offices, sovereign wealth funds, and institutional investors resembling participants in funds managed by Temasek and Qatar Investment Authority. Performance metrics for venture portfolios are informed by exits and valuation milestones, with notable liquidity events in peer firms often benchmarked against IPOs like Moderna and acquisitions like Illumina’s purchases. aMoon’s fundraising cadence reflects broader macro trends affecting capital flows in life sciences, comparable to cycles experienced by firms such as Third Rock Ventures and OrbiMed. The firm reports committed capital deployment across therapeutic and digital health funds, aligning with due diligence practices influenced by academic peer review processes from journals such as Nature and The Lancet.

Management and Governance

The management team combines entrepreneurs, clinicians, and investment professionals with track records in healthcare ventures and corporate boards. Senior leadership includes executives with prior roles in companies comparable to Allergan and Amgen, and advisors drawn from academic institutions such as Tel Aviv University and Columbia University. Governance practices involve board representation at portfolio companies, adherence to compliance frameworks modeled on standards used by firms like BlackRock and KKR, and engagement with legal counsel experienced in healthcare transactions including firms that represent clients before courts and regulators like the U.S. Securities and Exchange Commission. aMoon emphasizes scientific advisory boards comprising researchers associated with centers such as Dana–Farber Cancer Institute and Broad Institute.

Partnerships and Strategic Initiatives

aMoon pursues strategic partnerships with pharmaceutical corporations, hospital systems, academic research centers, and co-investors. Collaborative initiatives include acceleration programs resembling those run by JLABS and alliances with translational research centers like CIMIT. The firm has engaged in strategic initiatives to support commercialization pathways, including collaborations with contract research organizations typical in the industry such as ICON plc and Parexel, and partnerships with diagnostic manufacturers akin to Abbott Laboratories and Siemens Healthineers. International outreach includes relationships with regional venture ecosystems in hubs like Boston, San Francisco, and London to facilitate cross-border scaling.

Criticism and Controversies

Critiques of venture firms in life sciences apply to aMoon in areas such as valuation practices, exit timing, and alignment of incentives between investors and clinicians, issues similarly debated in cases involving Theranos and scrutiny surrounding biotech IPOs. Observers have raised questions about concentration risk in sector-focused funds and potential conflicts when syndicating with corporate partners such as Pfizer or Roche, reflecting concerns voiced in analyses of venture collaborations with industry. Regulatory scrutiny affecting portfolio companies—e.g., trials overseen by the U.S. Food and Drug Administration—can lead to setbacks and public debate, paralleling controversies in high-profile biotech firms like Biogen and Sarepta Therapeutics. Transparency and governance remain focal points for stakeholders tracking performance and ethical considerations in translational research investments.

Category:Venture capital firms